statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 PR Newswire VANCOUVER...

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

The Goldman Sachs Group began coverage on shares of Olema Pharmaceuticals (NASDAQ:OLMA - Free Report) in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The firm issued a...

Olema Pharmaceuticals (NASDAQ:OLMA) Coverage Initiated by Analysts at The Goldman Sachs Group

SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ( Olema or Olema Oncology , Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery...

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path...

Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA  Get Free Report) has earned an average recommendation of Buy from the seven brokerages that are currently covering the stock...

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Rating of "Buy" by Analysts

EP Wealth Advisors LLC increased its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA  Free Report) by 831.1% in the third quarter, according to its most recent Form 13F filing...

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Purchased by EP Wealth Advisors LLC

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA  Get Free Report)s share price shot up 11.9% during mid-day trading on Wednesday . The company traded as high as $13.59 and last traded at...

Olema Pharmaceuticals (NASDAQ:OLMA) Trading Up 11.9%

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA  Get Free Report) was the recipient of a significant drop in short interest during the month of February. As of February 29th, there was short interest...

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Short Interest Down 21.2% in February

Presented compelling clinical results for palazestrant both as a monotherapy and in combination with CDK4/6 inhibitors, ribociclib and palbociclib, in Q4 2023 Initiated OPERA-01 pivotal Phase 3...

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

This indicator may be signaling that OLMA's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Olema Pharmaceuticals (OLMA, $13.01) entered Downtrend as Momentum indicator drops below 0 level on Mar 08, 2024

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Watchers	947
52-Wk Low	$5.02
52-Wk High	$17.79

Volume	670,592.00
52-Wk High	$17.79
52-Wk Low	$5.02

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.54	--	--	N/A
Q4'23	-$0.49	-$0.49	-0.82%	MISSED
Q3'23	-$0.51	-$0.48	6.18%	BEAT
Q2'23	-$0.73	-$0.49	32.55%	BEAT
Q1'23	-$0.66	-$0.70	-5.60%	MISSED

OLMA Olema Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals